← Back to Analyst Consensus 
VTYX Hold
Ventyx Biosciences, Inc.
Current Price —
Implied Upside —
Analysts 15
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jan 8, 2026 | Oppenheimer | downgrade | Outperform → Perform | $0 | 52% |
| Jan 8, 2026 | Wells Fargo | downgrade | Overweight → Equal-Weight | $14 | 54% |
| Jan 8, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | $14 | 44% |
| Jan 8, 2026 | UBS | downgrade | Buy → Neutral | $14 | 54% |
| Jan 8, 2026 | LifeSci Capital | downgrade | Outperform → Market Perform | $14 | 57% |
| Jan 8, 2026 | Canaccord Genuity | downgrade | Buy → Hold | $14 | 48% |
| Jan 7, 2026 | UBS | initiate | — → Buy | $20 | 54% |
| Nov 7, 2025 | Canaccord Genuity | maintain | Buy → Buy | $16 | 48% |
| Nov 7, 2025 | Wells Fargo | maintain | Overweight → Overweight | $14 | 54% |
| Nov 5, 2025 | HC Wainwright & Co. | upgrade | Neutral → Buy | $18 | 44% |
| Oct 27, 2025 | Oppenheimer | maintain | Outperform → Outperform | $14 | 52% |
| Oct 1, 2025 | Clear Street | initiate | — → Buy | $11 | 47% |
| Jan 14, 2025 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $0 | 44% |
| Nov 11, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $6 | 44% |
| Nov 8, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $9 | 52% |
| Oct 15, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $6 | 44% |
| Sep 23, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $6 | 44% |
| Aug 12, 2024 | Wells Fargo | maintain | Overweight → Overweight | $11 | 54% |
| Aug 12, 2024 | Canaccord Genuity | maintain | Buy → Buy | $14 | 48% |
| Jul 30, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $6 | 44% |
| Jun 13, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $6 | 44% |
| Jun 6, 2024 | Oppenheimer | maintain | Outperform → Outperform | $10 | 52% |
| Jun 6, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $6 | 44% |
| Mar 13, 2024 | Canaccord Genuity | maintain | Buy → Buy | $15 | 48% |
| Mar 12, 2024 | Wells Fargo | upgrade | Equal-Weight → Overweight | $16 | 54% |
| Mar 12, 2024 | Oppenheimer | upgrade | Perform → Outperform | $12 | 52% |
| Mar 11, 2024 | Canaccord Genuity | maintain | Buy → Buy | $16 | 48% |
| Feb 21, 2024 | Oppenheimer | reiterate | — → Perform | $0 | 52% |
| Dec 19, 2023 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | $3 | 54% |
| Dec 18, 2023 | Stifel | maintain | Hold → Hold | $2 | 53% |
| Nov 10, 2023 | Evercore ISI Group | downgrade | Outperform → In-Line | $5 | 58% |
| Nov 7, 2023 | Morgan Stanley | downgrade | Overweight → Equal-Weight | $6 | 54% |
| Nov 7, 2023 | Stifel | downgrade | Buy → Hold | $6 | 53% |
| Nov 7, 2023 | HC Wainwright & Co. | downgrade | Buy → Neutral | $0 | 44% |
| Oct 10, 2023 | Stifel | reiterate | Buy → Buy | $56 | 53% |
| Oct 10, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $52 | 44% |
| Aug 29, 2023 | Morgan Stanley | maintain | Overweight → Overweight | $46 | 54% |
| Aug 11, 2023 | Credit Suisse | maintain | Outperform → Outperform | $62 | — |
| Aug 11, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $52 | 44% |
| Jul 5, 2023 | Oppenheimer | reiterate | Outperform → Outperform | $62 | 52% |
| Jul 5, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $54 | 44% |
| May 12, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $54 | 44% |
| Mar 24, 2023 | Credit Suisse | reiterate | — → Outperform | $63 | — |
| Mar 24, 2023 | Oppenheimer | maintain | — → Outperform | $62 | 52% |
| Mar 21, 2023 | Wells Fargo | initiate | — → Overweight | $77 | 54% |
| Mar 20, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $50 | 44% |
| Jan 31, 2023 | Canaccord Genuity | maintain | — → Buy | $54 | 48% |
| Jan 27, 2023 | Oppenheimer | maintain | — → Outperform | $60 | 52% |
| Dec 19, 2022 | Goldman Sachs | initiate | — → Buy | $50 | 54% |
| Nov 17, 2022 | Morgan Stanley | initiate | — → Overweight | $45 | 54% |
Price Target Trend
Apr 21, 2026 Latest: $13 May 3, 2026
EPS Estimates
+1q $-0.40
Lo: $-0.51 Hi: $-0.28
2 analysts ▲1
+1y $-1.57
Lo: $-2.08 Hi: $-1.23
4 analysts ▲1
0q $-0.39
Lo: $-0.49 Hi: $-0.29
4 analysts ▲1
0y $-1.48
Lo: $-1.57 Hi: $-1.37
4 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days